This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, Q. Articles by Wright, S. D. Search for Related Content PubMed PubMed Citation Articles by Guo, Q. Articles by Wright, S. D.

A Novel Peroxisome Proliferator-Activated Receptor / Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis

Departments of Atherosclerosis and Endocrinology (Q.G., P.-R.W., D.P.M., M.C.I., J.B., M.H., M.-H.L., C.P.S., Y.-S.C., S.D.W.), Metabolic Disorders (M.W., C.B., N.S., L.J.K., K.L.M., G.Z., T.W.D., J.P.B., D.E.M.), and Medicinal Chemistry (S.P.S., W.H., R.D., J.V.H.), Merck Research Laboratories, Rahway, New Jersey 07065-0900

Address all correspondence and requests for reprints to: Qiu Guo, R80W250, P.O. Box 2000, Merck & Co. Inc., Rahway, New Jersey 07065. E-mail: qiu_guo{at}merck.com.

Patients with type 2 diabetes mellitus exhibit hyperglycemia and dyslipidemia as well as a markedly increased incidence of atherosclerotic cardiovascular disease. Here we report the characterization of a novel arylthiazolidinedione capable of lowering both glucose and lipid levels in animal models. This compound, designated TZD18, is a potent agonist with dual human peroxisome proliferator-activated receptor (PPAR)-/ activities. In keeping with its PPAR activity, TZD18 caused complete normalization of the elevated glucose in db/db mice and Zucker diabetic fatty rats. TZD18 lowered both cholesterol and triglycerides in hamsters and dogs. TZD18 inhibited cholesterol biosynthesis at steps before mevalonate and reduced hepatic levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Moreover, TZD18 significantly suppressed gene expression of fatty acid synthesis and induced expression of genes for fatty acid degradation and triglyceride clearance. Studies on 17 additional PPAR or PPAR/ agonists showed that lipid lowering in hamsters correlated with the magnitude of hepatic gene expression changes. Importantly, the presence of PPAR agonism did not affect the relationship between hepatic gene expression and lipid lowering. Taken together, these data suggest that PPAR/ agonists, such as TZD18, affect lipid homeostasis, leading to an antiatherogenic plasma lipid profile. Agents with these properties may provide favorable means for treatment of type 2 diabetes and dyslipidemia and the prevention of atherosclerotic cardiovascular disease.

This article has been cited by other articles:

				L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741. [Abstract] [Full Text] [PDF]

				H. Liu, C. Zang, M. H. Fenner, D. Liu, K. Possinger, H. P. Koeffler, and E. Elstner Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPAR{alpha}/{gamma} ligand TZD18 Blood, May 1, 2006; 107(9): 3683 - 3692. [Abstract] [Full Text] [PDF]

				P. Shen, M. H. Liu, T. Y. Ng, Y. H. Chan, and E. L. Yong Differential Effects of Isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the Activation of PPAR{alpha}, PPAR{gamma}, and Adipocyte Differentiation In Vitro J. Nutr., April 1, 2006; 136(4): 899 - 905. [Abstract] [Full Text] [PDF]